| Name | CD1d molecules |
|---|---|
| Synonyms | CD1A; CD1D; CD1d antigen; CD1d molecule; R3; R3G1; T cell surface glycoprotein CD1d; T cell surface glycoprotein CD1d precursor… |
| Name | OCH |
|---|---|
| CAS | 2,3,4,4,5,5,6,6-octachloro-2-cyclohexen-1-one |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 17014832 | Lee A, Farrand KJ, Dickgreber N, Hayman CM, Jurs S, Hermans IF, Painter GF: Novel synthesis of alpha-galactosyl-ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr Res. 2006 Dec 11;341(17):2785-98. Epub 2006 Oct 2. alpha-Galactosyl- (1) has been identified as a powerful modulator of immunological processes through its capacity to bind CD1d molecules and specifically activate invariant natural killer (NK)-like T cells (iNKT cells). This paper describes the synthesis of 1, the analogous alpha-galactosyl- 3, and its short chain analogue 'OCH' (2), by use of the 4,6-di-O-tert-butylsilylene (DTBS) protecting group to produce a powerful alpha-galactosylating agent. |
1(0,0,0,1) | Details |
| 15173890 | Oki S, Chiba A, Yamamura T, Miyake S: The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest. 2004 Jun;113(11):1631-40. Furthermore, IFN-gamma production by NKT cells requires longer T cell receptor stimulation than is required for IL-4 production by NKT cells stimulated either with immobilized mAb to CD3 or with immobilized "alphaGC-loaded" CD1d molecules. |
1(0,0,0,1) | Details |
| 14607913 | Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V: NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003 Nov 15;171(10):5140-7. NKT cells bearing an invariant TCR (iNKT cells) restricted by nonpolymorphic CD1d molecules may constitute a readily available source of help for DC. |
2(0,0,0,2) | Details |
| 15860372 | Berkers CR, Ovaa H: Immunotherapeutic potential for -based activators of iNKT cells. Trends Pharmacol Sci. 2005 May;26(5):252-7. Invariant natural killer T (iNKT) cells are a subpopulation of T cells that are reactive with glycolipids that are bound by CD1d antigen-presenting molecules. alpha-Galactosylceramide (alpha-GalCer) is a synthetic glycolipid that is a potential treatment for several autoimmune diseases, infectious diseases and cancer. |
1(0,0,0,1) | Details |
| 18855664 | Araki M, Miyake S, Yamamura T: Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. Curr Med Chem. 2008;15(23):2337-45. Invariant natural killer T (iNKT) cells are an attractive therapeutic target in autoimmune diseases, since they play a major role in immune regulation. iNKT cells recognize glycolipid antigens presented by CD1d molecules that resemble the non-polymorphic MHC class I protein. alpha-galactosylceramide (alpha-GalCer) isolated from marine sponge has long been used as a prototype iNKT cell ligand in the laboratory. |
1(0,0,0,1) | Details |